The diagnostics company Gradientech today announces to have started its third FDA 510(k) clinical study site in the US for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST).
The diagnostics company Gradientech today announces to have started its third FDA 510(k) clinical study site in the US for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST).
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 17 December to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 60 million (the “Rights Issue”). A prospectus regarding the Rights Issue has today been approved by the Swedish Financial Supervisory Authority and is available on the Company’s website gradientech.se (https://gradientech.se/investors/rights-issue-2025).
The diagnostics company Gradientech announces the successful implementation of the QuickMIC[®] system for ultra-rapid antibiotic susceptibility testing (AST) into clinical routine use at the Molinette Hospital in Turin, Italy.
The diagnostics company Gradientech announces the presentation of newly published outstanding performance data on QuickMIC® at the 17th National Conference of Microbiology and Epidemiology in Iași, Romania, 7-9 November 2024.
Gradientech AB (publ) interim report for Q3 2024 is now available on the company’s website www.gradientech.se.
Gradientech AB (publ) (“Gradientech” or the “Company”) announced on October 8 the exclusive partnership with Hardy Diagnostics for the commercialisation of its QuickMIC[®] system in the United States and Canada. Alongside this partnership, Hardy Diagnostics decided to subscribe for 1,796,571 shares in Gradientech. Through the Issue, Gradientech will receive proceeds of approximately SEK 31.4 million before deduction of issue costs.
The diagnostics company Gradientech today announces the exclusive partnership with Hardy Diagnostics for the commercialisation of its QuickMIC® system in the United States and Canada. QuickMIC is an ultra-rapid antibiotic susceptibility testing (AST) system designed to provide critical results for sepsis patients. Alongside this partnership, Hardy Diagnostics has decided to invest in Gradientech, becoming one of the company’s largest shareholders.
The diagnostics company Gradientech announces a new scientific publication of the QuickMIC® system, the today fastest diagnostic system on the market for antibiotic susceptibility testing (AST) of blood cultures from patients with sepsis. The article is published in the top-tier Journal of Clinical Microbiology.
The diagnostics company Gradientech today announces to have started the 510(k) clinical study for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing at the first two clinical sites, both well-renowned hospitals in the US.
The diagnostics company Gradientech announces a new scientific publication of the QuickMIC® system by Dr. Balmis University General Hospital demonstrating an impressive concordance of 99% between QuickMIC and the reference methods in use.